Cearvol in Canada: what the research says

AssetThe demand story checks out

• The lane is genuinely empty. No distributor currently wholesales OTC-style devices to Canadian clinics, and no US OTC brand (Sony, Jabra, Lexie, Eargo) ever formally entered Canada. There is a real rung missing between "nothing" and $1,500.
• The Wave is credible hardware. Independent lab (HearAdvisor) scored it an "A" — top ~21% of all hearing aids tested, with an Expert Choice award. This is not AliExpress junk; an audiologist demoing it would not be embarrassed.
• Wave pricing survives the Google test. $498 CAD MSRP is at-or-below Cearvol's own US street price (~$397 USD ≈ $545 CAD). The flagship is the one model where the channel math holds.
• The US OTC die-off is a selling point for clinics. Eargo, Lexie, Sony's OTC line, Jabra Enhance Plus, and Lucid all shut down within ~12 months — "buy the cheap one online and there's no one to call" is now a documented fact, and local warranty through a clinic answers it.

BlockerRegulatory: the model is unlicensed today

• No OTC category exists in Canada. Hearing aids are Class II medical devices, full stop. Apple's AirPods feature was licensed as an ordinary Class II device — there is no lighter path.
• Intended use is set by the manufacturer, not by our re-label. Cearvol's manuals are titled "OTC Intelligent Hearing Aids"; cearvol.com sells them for mild-to-moderate hearing loss. Health Canada judges the totality of representation — calling them "situational lifestyle amplifiers" while selling through hearing clinics at hearing-aid prices reads as an unlicensed Class II device.
• Neither Cearvol, UNICE, nor Cannice appears in Health Canada's MDALL licence database (verified against the full active-licence extract). Legal import requires the manufacturer to obtain a Medical Device Licence (MDSAP audit first — realistically 6–12+ months and manufacturer-side money) plus a Medical Device Establishment Licence for the Toronto importer (~$5K/yr and documented recall/complaint procedures).
• Provincial dispensing law binds our customers. Ontario: no dispensing a hearing aid without a prescription (RHPA). Quebec: sale of hearing devices is reserved to audioprothésistes on a certificate of need — effectively a dead province. BC and Alberta regulate fitting/dispensing as restricted activities. Even Apple, licence in hand since Dec 2024, kept the feature geoblocked in Canada for over a year because of these laws.
• But the door is opening. CASLPO (Ontario's regulator) published a task-force report in March 2026 recommending an OTC exception modelled on the reading-glasses carve-out, and new Health Canada registry entries suggest Apple's Canadian launch is imminent. Whoever is licensed and standing in the clinic channel when that happens wins the window.

HeadwindsThree forces that squeeze the model

• Apple at $329. AirPods Pro with a Health Canada licence, a clinically validated hearing test, and Apple retail brackets our exact price band the day it switches on. Counter-story clinics can tell: ~6-hour wear battery, iPhone-only, no professional fitting, looks like you're ignoring people at dinner.
• Public funding neutralizes the price gap for the best patients. Ontario's ADP pays $1,000/pair, Quebec's RAMQ makes aids essentially free, and WSIB/VAC/NIHB cover prescribed aids — none of it applies to an amplifier. The addressable buyer is the patient who fails funding tests or balks at the net price anyway: real, but narrower than raw price comparison suggests.
• Clinic incentive math killed this model in the US. $150–$300 gross per unit competes for chair time with $2,000+ prescription sales — the same arithmetic that sank Sonova's Sennheiser clinic-channel OTC experiment (now being divested). The pitch must be "capture the walkout you were losing entirely," and the merchandising must cost the clinic nearly zero effort.

VendorCearvol / UNICE due diligence

• Young vendor, thin track record. UNICE (the medical entity) was founded in 2023. The Wave has ~46 Amazon ratings at 3.6★, inventory runs thin, and there is no existing clinic program or named distributor anywhere — though they are actively courting professional channels (AAA, EUHA, CES booths; a dealer form on their Japanese site).
• "FDA-registered" ≠ FDA-cleared. The devices sit in the 510(k)-exempt OTC category; no 510(k) exists. Sell sheets must never say "FDA-cleared" or "self-fitting."
• Zero MAP history and a perpetual-discount culture. Every model is permanently "on sale" 20–30% off, with affiliate coupons. Nothing stops them launching Amazon.ca beneath our clinics tomorrow. Any deal needs, in writing: Canada exclusivity, MAP, and a no-Amazon.ca commitment — things this vendor has never done for anyone.
• The line should probably shrink to the Wave (± Liberte). Nano 2 at ~$458 CAD against a $269 USD (≈$369 CAD) US listing fails the parking-lot Google test; Diamond-class hardware is commoditized Shenzhen product available under many names below $150.

Scroll the table sideways on narrow screens.

What this means for the site we already built

The build itself (cinematic trade funnel at otc.lotouch.ca) is strong craft and most of it survives a repositioning. The copy does not:

• The brand name imports a US legal category that doesn't exist here. "OTC Hearing Tech" asserts the very framing Health Canada doesn't recognize — and our audience (clinicians) knows it.
• The footer disclaimer is self-incriminating. "PSAPs designed for adults managing mild to moderate hearing impairment" is precisely the intended-use claim that makes a device a hearing aid, not a PSAP.
• Medical claims are scattered through the copy: "clinical-grade compensation via the NAL-NL2 prescription formula," "evidence-based hearing compensation," "clinically safe by design," "hidden hearing loss." Under the Competition Act, performance claims also need pre-existing substantiation.
• "FDA Listed / NMPA Qualified" badges are US/China credentials shown to the one audience guaranteed to ask "where's Health Canada?"
• Bilingual obligations are unaddressed: packaging/label law requires French nationwide; Quebec's Bill 96 requires French manuals, warranty docs, and app — though if Quebec is out of scope anyway, this shrinks to packaging basics.
• Hard promises are baked in — guaranteed 50% margin, national MAP enforcement, 45-day take-back, 3-year warranty (which we'd be honouring from Toronto unless UNICE commits). Each needs an operational answer before a clinic holds us to it.

Paths forward

Questions to settle at the regroup

• What is the actual relationship with UNICE — a distribution conversation, a signed agreement, or an idea from a trade show? Who talks to them about Canadian licensing, and what leverage do we have?
• Is Alex's father prepared for a 6–12 month, compliance-heavy runway (MDEL, recall procedures, French labelling) rather than a quick import play?
• Who backs the 3-year warranty and 45-day take-back operationally — Toronto stock and RMA, or Shenzhen turnaround?
• Scope: are we content to write off Quebec and lead with Ontario plus the prairies?
• Does the brand keep the "OTC" name (betting on the carve-out making it accurate) or rename now?